Ponatinib

CAS Number: 943319-70-8

Molecular Formula: C29H27F3N6O

About Ponatinib

Ponatinib (CAS 943319-70-8), a potent third-generation BCR-ABL tyrosine kinase inhibitor, is currently experiencing a surge in demand as a critical high purity fine chemical for the treatment of T315I-mutated chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in the United States. Iclusig, as the primary com...

Ponatinib Specifications

CAS Number

943319-70-8

Molecular Formula

C29H27F3N6O

Molecular Weight

532.57 g/mol

IUPAC Name

3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide

Canonical SMILES

CCC1(CCC2C1(CCC3C2CCC4=CCCCC34)C)O

InChI Key

PHXJVRSECIGDHY-UHFFFAOYSA-N

PubChem CID

24826799

CAS Number

943319-70-8

Molecular Formula

C29H27F3N6O

Molecular Weight

532.57 g/mol

IUPAC Name

3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide

Canonical SMILES

CCC1(CCC2C1(CCC3C2CCC4=CCCCC34)C)O

InChI Key

PHXJVRSECIGDHY-UHFFFAOYSA-N

PubChem CID

24826799

Molecular Weight

532.57 g/mol

Antineoplastic Agent

A potent third-generation multi-targeted tyrosine kinase inhibitor (TKI) primarily used for the treatment of adult patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL), particularly in cases involving the T315I mutation or resistance to prior kinase inhibitor therapies

Pharmaceutical Intermediate

A high-purity active pharmaceutical ingredient (API) utilized in clinical research and drug development to study BCR-ABL protein inhibition and overcome multi-drug resistance in hematologic malignancies

Biochemical Tool

A critical research compound used in molecular biology and oncology studies to inhibit various tyrosine kinases including KIT, PDGFRA, FGFR1, and FLT3 for targeted cancer therapy evaluation.